Gilead Sciences Inc (GILD)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$138.44

Buy

$140.05

arrow-up$3.03 (+2.22%)

Prices updated at 31 Mar 2026, 10:57 EDT

Prices minimum 15 mins delay

Prices in USD

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

NASDAQ

3.83%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Mr. Daniel P. O'Day

CEO

Mr. Daniel P. O'Day

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

17,000

Head office

333 Lakeside Drive

Foster City

United States

94404

+1 650 574-3000

investor_relations@gilead.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Andrew D. Dickinson Chief Financial Officer	1.12m
Mr. Anthony Welters Lead Independent Director	0.18m
Dr. Jacqueline K. Barton, PhD Independent Director	0.12m
Mr. Javier J. Rodriguez Independent Director	0.10m
Dr. Ted W. Love, M.D. Independent Director	0.10m
Mr. Harish Manwani Independent Director	0.13m
Ms. Kelly Anne Kramer Independent Director	0.14m
Mr. Daniel P. O'Day Chairman of the Board and Chief Executive Officer	1.80m
Dr. Sandra J. Horning, M.D. Independent Director	0.13m
Dr. Dietmar Berger, M.D.,PhD Chief Medical Officer	0.97m
Dr. Jeffrey A. Bluestone, PhD Independent Director	0.10m
Ms. Johanna Mercier Chief Commercial and Corporate Affairs Officer	1.18m
Ms. Erin Burkhart Senior Vice President, Controllership and Principal Accounting Officer	-
Ms. Keeley M. Cain Wettan Executive Vice President, Legal and Compliance and General Counsel	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	121,097,336
BlackRock Inc	116,281,391
Capital Research and Management Company	67,549,546
FMR Inc	65,579,490
Fidelity Management and Research Company	65,579,490

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Dec 2025	-
15 Dec 2025	-
15 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
10 Dec 2025	-
28 Nov 2025	-
28 Nov 2025	-
28 Nov 2025	-
28 Nov 2025	-
28 Nov 2025	-
26 Nov 2025	-
28 Nov 2025	-
28 Nov 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.